Epigen Biosciences, Inc.
Epigen Biosciences is a pharmaceutical company dedicated to discovering innovative, proprietary drugs to address unmet medical needs. They focus on developing novel therapeutics across multiple areas, leveraging advanced drug discovery techniques, collaborations, and a team with over 50 years of experience. Their mission is to develop therapies that improve quality of life for patients by bridging the gap from laboratory research to clinical application, with an aim for rapid development timelines.
Industries
Nr. of Employees
small (1-50)
Epigen Biosciences, Inc.
San Diego, California, United States, North America
Products
LPA1 receptor antagonist (small molecule)
A selective small-molecule antagonist of LPA1 being developed for indications including diabetic kidney disease, non-alcoholic steatohepatitis (NASH/MASH) and idiopathic pulmonary fibrosis.
Sigma-1 receptor ligands (small molecules)
Selective small-molecule ligands targeting the sigma-1 receptor being developed for Alzheimer’s disease and other neurodegenerative conditions such as ALS and Fragile X-associated disorders.
p70 S6 kinase inhibitors (small molecules)
Small-molecule inhibitors of p70 S6 kinase developed as disease-modifying candidates for Fragile X syndrome based on modulation of translational control pathways.
α7 nicotinic receptor positive allosteric modulators (PAM-II, small molecules)
Positive allosteric modulators of the α7 nicotinic acetylcholine receptor intended to augment endogenous therapeutic pathways for indications including stroke and traumatic brain injury.
LPA1 receptor antagonist (small molecule)
A selective small-molecule antagonist of LPA1 being developed for indications including diabetic kidney disease, non-alcoholic steatohepatitis (NASH/MASH) and idiopathic pulmonary fibrosis.
Sigma-1 receptor ligands (small molecules)
Selective small-molecule ligands targeting the sigma-1 receptor being developed for Alzheimer’s disease and other neurodegenerative conditions such as ALS and Fragile X-associated disorders.
p70 S6 kinase inhibitors (small molecules)
Small-molecule inhibitors of p70 S6 kinase developed as disease-modifying candidates for Fragile X syndrome based on modulation of translational control pathways.
α7 nicotinic receptor positive allosteric modulators (PAM-II, small molecules)
Positive allosteric modulators of the α7 nicotinic acetylcholine receptor intended to augment endogenous therapeutic pathways for indications including stroke and traumatic brain injury.
Services
Collaborative drug discovery and development
Project-based discovery partnerships providing medicinal chemistry, hit-to-lead and lead optimization, computational design, ADME profiling and preclinical development support to advance small-molecule assets toward IND.
Collaborative drug discovery and development
Project-based discovery partnerships providing medicinal chemistry, hit-to-lead and lead optimization, computational design, ADME profiling and preclinical development support to advance small-molecule assets toward IND.
Expertise Areas
- Small-molecule drug discovery
- Medicinal chemistry and lead optimization
- Preclinical ADME/Toxicology and pharmacology
- In vitro assay development and cellular disease models
Key Technologies
- Computational drug design
- Focused library synthesis
- High-throughput and cell-based screening
- Cerebral organoids (3D in vitro models)